Drug Trial Radar · NCT04129502
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
354
Actual
Start
Jan 10, 2020
Primary completion
Sep 22, 2026
Study completion Sep 22, 2026
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Oct 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group. Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.
Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
TAK-788Drug
TAK-788 capsule
PemetrexedDrug
Pemetrexed IV infusion
CisplatinDrug
Cisplatin IV infusion
CarboplatinDrug
Carboplatin IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Up to approximately 40 months after the first participant is randomized
Locations
134 sites in 24 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Long Beach, California
University of California Irvine
Orange, California
Stanford University
Palo Alto, California
AdventHealth
Orlando, Florida
Northwestern University
Chicago, Illinois
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland
Beth Israel Deaconess Medical Center - 330 Brookline Ave
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Sarah Cannon Cancer Center
Nashville, Tennessee
University of Virginia Health System
Charlottesville, Virginia
GenesisCare North Shore
St Leonards, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Klinik Floridsdorf
Vienna, Austria
Cliniques Universitaires Saint-Luc
Brussels, Brussels Capital, Belgium
Grand Hopital de Charleroi asbl
Charleroi, Hainaut, Belgium
AZ Sint-Lucas
Aalst, Oost-Vlaanderen, Belgium
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
William Osler Health System
Brampton, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Hopital Du Sacre Coeur de Montreal
Montreal, Quebec, Canada
Beijing Cancer Hospital - PPDS
Beijing, China
Beijing Chest Hospital, Capital Medical Univerity
Beijing, China
Icahn School of Medicine at Mount Sinai
Beijing, China
Sichuan Cancer Hospital & Institute
Chengdu, China
Guangdong Provincial People's Hospital
Guangzhou, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Harbin Medical University Tumor Hospital
Harbin, China
Shanghai East Hospital
Shanghai, China
Hubei Cancer Hospital
Wuhan, China
Beijing Cancer Hospital - PPDS
Beijing, Beijing Municipality, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Jilin Cancer Hospital
Changchun, Jilin, China
CHU de Grenoble
Grenoble, France
Hopital Nord AP-HM
Marseille, France
CRLC Val d'Aurelle - Paul Lamarque
Montpellier, France
Hopital Tenon
Paris, France
Nouvel Hopital Civil
Strasbourg, France
Hopital Larrey
Toulouse, France
Showing 40 of 134 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.